All Episodes
FDA Watch — 51 episodes
Insights on Evidence and Communication with FDA in Device Submissions
Cautious Optimism Surrounding Rare Diseases and Orphan Drugs
FDA's Regulatory Revisions: Business & Legal Impact on Industry, Part 3 – Foods
FDA's Regulatory Revisions: Business & Legal Impact on Industry, Part 2 – Medical Devices
FDA's Regulatory Revisions: Business & Legal Impact on Industry, Part 1 – Pharmaceuticals
Medical Device Regulation, Compliance & Policy, Part 4: Digital Health & Consumers
Medical Device Regulation, Compliance & Policy, Part 3: On False Claims
FDA Reporter Roundtable: A View From the News Desk
'Forever Chemicals' and Cosmetics Oversight in 2026
Medical Device Regulation, Compliance & Policy, Part 2: A Look at Europe & China
FDA's 2026 Food Priorities
Medical Device Regulation, Compliance & Policy, Part 1: LDTs in Focus
FDA's Evolving Approach to Medical Device Reviews
Inside FDA Pharma Policy Development
Year-End Review & Look Ahead
Deregulation, AI & More with Dr. Ritu Nalubola
Pharmaceutical Regulation, Compliance & Policy, Part 4: Dispute Resolution for Drugs and Biological Products
Key Issues Shaping Cosmetics and Personal Care Oversight
How Industry Is Adapting to FDA's Food Shifts
Pharmaceutical Regulation, Compliance & Policy, Part 3: A Close Look at Generic Drugs
Pharmaceutical Regulation, Compliance & Policy, Part 2: Navigating the New Enforcement Environment
Examining CDRH, Device Innovation & Agency Communication
A Look at FDA's Drug Review Reset
Pharmaceutical Regulation, Compliance & Policy, Part 1: The Evolving Regulatory Landscape of Rare Diseases
Unpacking OMUFA
FDA's Fight Against Ultraprocessed Foods
Dissecting the Direction of CDER and CBER with Paul Kim
Medical Device Oversight in a Changing Landscape
Vaccines, Pharmaceutical Policy & FDA's Next Moves
FDA's Past, Present & Future with John Taylor
The Top 3 Developments of 2025 in Pharma, Devices, Cosmetics & Food
Breaking Down Cosmetics Safety, Imports & MoCRA
AI, Medical Products & FDA, Part 3: AI in Drug & Device Commercialization
Homing in on Food Supply, Tariffs & Infant Formula
AI, Medical Products & FDA, Part 2: AI Discovery, Design & Development
Devices, Disruption & the Road Ahead
Breaking Down Pharma in the Current Environment
The State of Protection, Innovation & Communication at FDA
AI, Medical Products & FDA, Part 1: AI Overview in Life Sciences
Examining the Cosmetics Compliance and Enforcement Landscape
A New Era of Unprecedented Change
The Latest in FDA's Focus on Foods
What's Happening in Software and Device Regulation
The Evolution of Clinical Trials
Navigating FDA's Future: Janet Woodcock on the Evolving Regulatory Landscape
A Deep Dive Into MoCRA
Food Regulation and Safety Under the New Administration
The New-Look FDA: What's on the Horizon?
What's Coming in Device, Cybersecurity, and Digital Health Product Regulation
Key Pharmaceutical Regulation Issues for the New Administration
Trailer